Lilly grabs glucose-sensing insulin tech, buying Protomer in $1bn dealEli Lilly bought a stake in Protomer Technologies and its glucose-sensing insulin platform last year, and it must Share XLilly grabs glucose-sensing insulin tech, buying Protomer in $1bn dealhttps://pharmaphorum.com/news/lilly-grabs-glucose-sensing-insulin-tech-buying-protomer-in-1bn-deal/
Boehringer, Lilly hail Jardiance data in hard-to-treat heart failureBoehringer Ingelheim and Eli Lilly have the results they were hoping for in a large-scale study of Jardiance Share XBoehringer, Lilly hail Jardiance data in hard-to-treat heart failurehttps://pharmaphorum.com/news/boehringer-lilly-hail-jardiance-data-in-hard-to-treat-heart-failure/
AZ closes in Forxiga kidney disease label in EU after nod from CHMPAstraZeneca’s fast-growing SGLT2 inhibitor Forxiga could soon get a further boost from approval in the EU as a Share XAZ closes in Forxiga kidney disease label in EU after nod from CHMPhttps://pharmaphorum.com/news/az-closes-in-forxiga-kidney-disease-label-in-eu-after-nod-from-chmp/
BMS re-joins Alzheimer’s push, paying $80m for Prothena’s tau antibodyJust a few days after Biogen abandoned its tau-targeting Alzheimer’s disease candidate gosuranemab, Bristol-Myers Squibb has opted into Share XBMS re-joins Alzheimer’s push, paying $80m for Prothena’s tau antibodyhttps://pharmaphorum.com/news/bms-re-joins-alzheimers-push-paying-80m-for-prothenas-tau-antibody/
Farxiga faces first heart failure rival as EU OKs Boehringer/Lilly’s JardianceAstraZeneca’s SGLT2 inhibitor Farxiga has been growing fast thanks to a first-in-class approval in heart failure, but will Share XFarxiga faces first heart failure rival as EU OKs Boehringer/Lilly’s Jardiancehttps://pharmaphorum.com/news/farxiga-faces-first-heart-failure-rival-as-eu-oks-boehringer-lillys-jardiance/
Scotland backs rare blood cancer drug Poteligeo rejected by NICEA north-south divide has emerged in UK medicines access after the Scottish Medicines Consortium (SMC) okayed Kyowa Kirin’s Share XScotland backs rare blood cancer drug Poteligeo rejected by NICEhttps://pharmaphorum.com/news/scotland-backs-rare-blood-cancer-drug-poteligeo-rejected-by-nice/
FDA ends 7-year obesity drug drought, clearing Novo Nordisk’s WegovyNovo Nordisk is celebrating the FDA approval of its GLP-1 agonist semaglutide as a treatment for obesity, which Share XFDA ends 7-year obesity drug drought, clearing Novo Nordisk’s Wegovyhttps://pharmaphorum.com/news/fda-ends-obesity-drug-drought/
Chasing Lilly, Concert eyes 2023 filing for its JAK drug for alopeciaConcert Pharmaceuticals has started the second of two planned phase 3 trials of its drug candidate for alopecia Share XChasing Lilly, Concert eyes 2023 filing for its JAK drug for alopeciahttps://pharmaphorum.com/news/chasing-lilly-concert-eyes-2023-filing-for-its-jak-drug-for-alopecia/
Trial win sets up filings for Lilly’s diabetes blockbuster hope tirzepatideEli Lilly has scored five out of five with its phase 3 trials of type 2 diabetes candidate Share XTrial win sets up filings for Lilly’s diabetes blockbuster hope tirzepatidehttps://pharmaphorum.com/news/final-trial-win-sets-up-filings-for-lillys-diabetes-blockbuster-hope-tirzepatide/
